B2M and neoplasm: A second trial evaluated 50 patients with stage II to IV FL and low tumour burden (no nodal or extranodal mass > 7 cm, B symptoms, splenomegaly, pleural effusion, ascites, organ compression, and elevated serum lactate dehydrogenase or beta-2-microglobulin) [32].